{"id":45157,"date":"2025-10-29T14:26:54","date_gmt":"2025-10-29T06:26:54","guid":{"rendered":"https:\/\/flcube.com\/?p=45157"},"modified":"2025-10-29T14:26:55","modified_gmt":"2025-10-29T06:26:55","slug":"qyuns-therapeutics-partners-with-roche-for-global-rights-to-long%e2%80%91acting-bispecific-antibody-qx031n","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45157","title":{"rendered":"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N"},"content":{"rendered":"\n<p>Qyuns Therapeutics\u202fCo.,\u202fLtd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2509:HKG\">HKG: 2509<\/a>) today announced a global exclusive collaboration and licensing agreement with <strong>F.\u202fHoffmann\u2011La Roche Ltd.<\/strong> (Roche) for <strong>QX031N<\/strong>, a self\u2011developed, long\u2011acting bispecific antibody targeting autoimmune diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\"><strong>Deal Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Rights<\/strong> \u2013 Roche will hold global exclusive rights to research, development, registration, manufacture and commercialization of QX031N.<\/li>\n\n\n\n<li><strong>Financial Terms<\/strong> \u2013 Qyuns receives an upfront, non\u2011refundable payment of <strong>USD\u202f75\u202fmillion<\/strong> and is eligible for up to <strong>USD\u202f995\u202fmillion<\/strong> in milestone payments tied to product development, regulatory approval and commercialization, plus tiered royalties on future sales.<\/li>\n\n\n\n<li><strong>Strategic Fit<\/strong> \u2013 The partnership leverages Roche\u2019s global commercialization platform with Qyuns\u2019 innovative bispecific platform.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-qx031n-a-first-in-class-best-in-disease-candidate\"><strong>QX031N \u2013 A First\u2011in\u2011Class, Best\u2011in\u2011Disease Candidate<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 QX031N injection simultaneously targets <strong>TSLP<\/strong> (Thymic Stromal Lymphopoietin) and <strong>IL\u201133<\/strong> (Interleukin\u201133).<\/li>\n\n\n\n<li><strong>Therapeutic Potential<\/strong> \u2013 Designed as a long\u2011acting therapy for respiratory autoimmune conditions, notably <strong>COPD<\/strong> and <strong>asthma<\/strong>, with the intent to become the first\u2011in\u2011class and best\u2011in\u2011disease treatment in these indications.<\/li>\n\n\n\n<li><strong>Development Roadmap<\/strong> \u2013 Qyuns will advance pre\u2011clinical studies, while Roche will spearhead clinical development, regulatory submissions and global marketing.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Qyuns Therapeutics\u202fCo.,\u202fLtd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F.\u202fHoffmann\u2011La&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45159,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,1239,495,163],"class_list":["post-45157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-hkg-2509","tag-qyuns-therapeutics","tag-roche"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Qyuns Therapeutics\u202fCo.,\u202fLtd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F.\u202fHoffmann\u2011La Roche Ltd. (Roche) for QX031N, a self\u2011developed, long\u2011acting bispecific antibody targeting autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45157\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N\" \/>\n<meta property=\"og:description\" content=\"Qyuns Therapeutics\u202fCo.,\u202fLtd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F.\u202fHoffmann\u2011La Roche Ltd. (Roche) for QX031N, a self\u2011developed, long\u2011acting bispecific antibody targeting autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45157\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T06:26:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T06:26:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2906.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N\",\"datePublished\":\"2025-10-29T06:26:54+00:00\",\"dateModified\":\"2025-10-29T06:26:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157\"},\"wordCount\":219,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2906.webp\",\"keywords\":[\"Auto-immune\",\"HKG: 2509\",\"QYuns Therapeutics\",\"Roche\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45157#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45157\",\"name\":\"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2906.webp\",\"datePublished\":\"2025-10-29T06:26:54+00:00\",\"dateModified\":\"2025-10-29T06:26:55+00:00\",\"description\":\"Qyuns Therapeutics\u202fCo.,\u202fLtd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F.\u202fHoffmann\u2011La Roche Ltd. (Roche) for QX031N, a self\u2011developed, long\u2011acting bispecific antibody targeting autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45157\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2906.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2906.webp\",\"width\":1080,\"height\":608,\"caption\":\"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45157#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N - Insight, China&#039;s Pharmaceutical Industry","description":"Qyuns Therapeutics\u202fCo.,\u202fLtd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F.\u202fHoffmann\u2011La Roche Ltd. (Roche) for QX031N, a self\u2011developed, long\u2011acting bispecific antibody targeting autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45157","og_locale":"en_US","og_type":"article","og_title":"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N","og_description":"Qyuns Therapeutics\u202fCo.,\u202fLtd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F.\u202fHoffmann\u2011La Roche Ltd. (Roche) for QX031N, a self\u2011developed, long\u2011acting bispecific antibody targeting autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=45157","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-29T06:26:54+00:00","article_modified_time":"2025-10-29T06:26:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2906.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45157#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45157"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N","datePublished":"2025-10-29T06:26:54+00:00","dateModified":"2025-10-29T06:26:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45157"},"wordCount":219,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45157#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2906.webp","keywords":["Auto-immune","HKG: 2509","QYuns Therapeutics","Roche"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45157#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45157","url":"https:\/\/flcube.com\/?p=45157","name":"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45157#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45157#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2906.webp","datePublished":"2025-10-29T06:26:54+00:00","dateModified":"2025-10-29T06:26:55+00:00","description":"Qyuns Therapeutics\u202fCo.,\u202fLtd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F.\u202fHoffmann\u2011La Roche Ltd. (Roche) for QX031N, a self\u2011developed, long\u2011acting bispecific antibody targeting autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45157#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45157"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45157#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2906.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2906.webp","width":1080,"height":608,"caption":"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45157#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Qyuns Therapeutics Partners with Roche for Global Rights to Long\u2011Acting Bispecific Antibody QX031N"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2906.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45157"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45157\/revisions"}],"predecessor-version":[{"id":45160,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45157\/revisions\/45160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45159"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}